NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a company “Advancing Drugs Through Glycoscience®", today announced it has entered into a research collaboration with The Brigham and Women’s Hospital to evaluate the anti-fibrotic effects of some of the Company’s novel, carbohydrate compounds to treat acute and chronic kidney disease. Brigham and Women’s Hospital is one of the largest, most respected research hospitals in the country. Pro-Pharmaceuticals is engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases, and viral infections.
